Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 357.00
Bid: 354.00
Ask: 360.00
Change: -13.00 (-3.51%)
Spread: 6.00 (1.695%)
Open: 370.00
High: 370.00
Low: 357.00
Prev. Close: 370.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Shareholder Meetings Calendar - Next 7 Days

Fri, 23rd Oct 2020 16:04

Monday 26 October 
Marechale Capital PLCAGM
All Active Asset Capital LtdAGM
Tuesday 27 October 
City of London Investment Trust PLCAGM
Filtronic PLCAGM
Tlou Energy LtdAGM
Accrol Group Holdings PLCAGM
Brooks Macdonald Group PLCAGM
Rolls-Royce Holdings PLCGM re rights issue
MyCelx Technologies CorpAGM
Oriole Resources PLCGM - re fund raise
Dechra PharmaceuticalsAGM
Wednesday 28 October 
Petra Diamonds LtdAGM
Zoetic International PLCAGM
Ideagen PLCAGM
Redde Northgate PLCAGM
Watchstone Group PLCGM re Ingenie disposal
Thursday 29 October 
Scancell Holdings PLCGM - re open offer and Redmile convertible loan notes issue
Rosslyn Data Technologies PLCAGM
Zoltav Resources IncAGM
ITM Power PLCAGM
Jarvis Securities PLCEGM re 4 for 1 subdivision of shares
i3 Energy PLCGM re reverse takeover of Toscana Energy Income
Friday 30 October 
MaxCyte IncAGM
Atlas Mara LtdAGM
Clinigen Group PLCAGM
Vietnam Holding LtdGM re shares tender, fee arrangements
Ferro-Alloy Resources LtdAGM
Springfield Properties PLCAGM
Zanaga Iron Ore Co LtdAGM
Sensyne Health PLCAGM
Intosol Holdings PLCAGM
Smartspace Software PLCAGM
Anglesey Mining PLCAGM
Gateley Holdings PLCAGM
  
Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
21 Feb 2020 11:53

MaxCyte to consolidate stock to single trading line

(Sharecast News) - Life sciences company MaxCyte announced the consolidation of its two lines of common stock into a single unrestricted line of common stock on Friday.

Read more
20 Jan 2020 10:58

MaxCyte 'exceptionally positive' following strong FY trading performance

(Sharecast News) - Clinical-stage life sciences company MaxCyte told investors on Monday that its board was "exceptionally positive" of the group's future following a stellar year.

Read more
20 Jan 2020 09:00

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

Read more
4 Dec 2019 16:14

MaxCyte inks new development agreement with KSQ Therapeutics

(Sharecast News) - Cell-based therapeutics and life sciences company MaxCyte has entered into a new development and commercialisation agreement with its existing partner KSQ Therapeutics, it announced on Wednesday.

Read more
4 Dec 2019 11:50

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics

Read more
21 Nov 2019 18:55

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma

Read more
21 Nov 2019 16:40

MaxCyte strikes deal with oncology company Vor Biopharma

(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.

Read more
24 Oct 2019 12:53

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11

Read more
7 Oct 2019 12:23

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included

Read more
18 Sep 2019 11:59

MaxCyte Interim Rises Revenue But Loss Widens On CARMA Investment

(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose

Read more
11 Sep 2019 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 12 September WM Morrison SupermarketsHalf Year ResultsBrooks MacdonaldFull Year

Read more
17 Jul 2019 13:43

MaxCyte Progresses On MCY-M11 Development As Interim Revenue Rises

(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is

Read more
26 May 2019 21:53

Sunday share tips: IQE, MaxCyte

(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.

Read more
8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Read more
8 May 2019 12:11

MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial

LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.